Berahyaluronidase Alfa / Pembrolizumab
Berahyaluronidase Alfa/Pembrolizumab is a combination medication that pairs a recombinant hyaluronidase enzyme with pembrolizumab, a programmed death-1 (PD-1) inhibitor. The hyaluronidase component facilitates subcutaneous drug delivery by temporarily breaking down hyaluronic acid in the subcutaneous space, while pembrolizumab works as an immunotherapy agent to help the immune system attack cancer cells. This combination is designed to allow pembrolizumab to be administered via subcutaneous injection rather than intravenous infusion.
A combination of an enzyme and immunotherapy agent designed to enable subcutaneous delivery of pembrolizumab for cancer treatment.
Key facts at a glance
- RxNorm
- 2723757
- Generic
- Berahyaluronidase Alfa / Pembrolizumab
- Class
- multi-ingredient
- Brands
- Keytruda Qlex
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
This combination is intended to treat various cancers where pembrolizumab is indicated, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and other malignancies approved for pembrolizumab therapy. Specific approved indications should be confirmed with current prescribing information.
Berahyaluronidase alfa breaks down hyaluronic acid in the subcutaneous tissue, temporarily expanding the space and allowing for better dispersion and absorption of co-administered medications. Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 on tumor cells, thereby restoring T-cell immune surveillance and anti-tumor activity.
Administered as a subcutaneous injection. Contraindicated in patients with known severe hypersensitivity to any component. Immune-mediated adverse reactions can occur, including pneumonitis, colitis, hepatitis, and endocrinopathies. Requires monitoring for infusion-related reactions and immune-related side effects. Pregnancy category D - may cause fetal harm. Clinical efficacy and safety profile should be confirmed with current regulatory approvals.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 28, 2026. · Read our editorial policy